Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebraca Wafer (Everfront Biotech Inc.)
- Development stage
- Unknown
- Lead developer
- Everfront Biotech
- Modality
- Small Molecules
- Administration
- Implantation
01
Overview
Cerebraca Wafer (EF-001) is a biodegradable implantable drug delivery system developed by Everfront Biotech for the treatment of glioblastoma multiforme (GBM). It consists of a wafer formulation containing EF-API-001, a novel small molecule designed to multi-target the AXL receptor tyrosine kinase, the PD-L1 immune checkpoint, and the MGMT DNA repair enzyme. By inhibiting AXL, the drug targets brain tumor stem cells to suppress growth and metastasis; by targeting PD-L1, it modulates the immunosuppressive tumor microenvironment; and by inhibiting MGMT, it overcomes tumor resistance to alkylating chemotherapeutic agents like temozolomide. The wafer is surgically implanted into the brain cavity following tumor resection, providing sustained drug release and high local concentrations for approximately one month.
- Brand names
- Cerebraca Wafer
- Other names
- Cerebraca
02
Targets
AXL (AXL receptor tyrosine kinase)DNMT1 (DNA (cytosine-5)-methyltransferase 1)AGT (O6-methylguanine-DNA methyltransferase)CD274 (Programmed cell death protein 1 ligand 1)TDO2 (Tryptophan 2,3-dioxygenase)
Beyond the preview
Go deeper on Cerebraca Wafer (Everfront Biotech Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerebraca Wafer (Everfront Biotech Inc.).